Veru (VERU) Change in Account Payables (2015 - 2026)
Veru (VERU) posted quarterly Change in Account Payables of $298223.0 for Q1 2026, up 176.34% year-over-year from $107918.9 in Q1 2025, and up 116.01% quarter-over-quarter from -$1.9 million in Q4 2025.
Veru (VERU) Change in Account Payables (2015 - 2026) Analysis & Trends
Veru (VERU) has reported Change in Account Payables for 12 consecutive years, with $298223.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Change in Account Payables rose 176.34% year-over-year to $298223.0; the TTM figure through Mar 2026 stood at -$2.7 million (down 63.2% YoY), while the FY2025 annual figure was -$2.8 million, up 49.19% from the prior year.
- Change in Account Payables advanced to $298223.0 in Q1 2026 per VERU's latest filing, from -$1.9 million in the prior quarter.
- Across five years, Change in Account Payables topped out at $15.1 million in Q3 2022 and bottomed at -$11.4 million in Q4 2022.
- Historically, Change in Account Payables has averaged -$53745.3 across 5 years, with a median of -$581759.0 in 2022.
- On a YoY basis, Change in Account Payables climbed as much as 1092.62% in 2022 and fell as far as 1786.95% in 2022.
- Veru's Change in Account Payables stood at -$11.4 million in 2022, then soared by 78.18% to -$2.5 million in 2023, then surged by 48.6% to -$1.3 million in 2024, then plunged by 45.24% to -$1.9 million in 2025, then soared by 116.01% to $298223.0 in 2026.
- Business Quant data shows VERU's Change in Account Payables at $298223.0 in Q1 2026, -$1.9 million in Q4 2025, and -$860779.0 in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -8.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 37.53 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Veru | 60.85 Mn | 35.06 Mn | - | -711,684.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -711,684.00 |
| Jun 30, 2026 | -711,684.00 |
| Mar 31, 2026 | 298,223.00 |
| Mar 31, 2026 | 298,223.00 |
| Dec 31, 2025 | -1.86 Mn |
| Dec 31, 2025 | -1.86 Mn |
| Sep 30, 2025 | -860,779.00 |
| Sep 30, 2025 | -860,779.00 |
| Jun 30, 2025 | -226,403.00 |
| Jun 30, 2025 | -226,403.00 |
| Mar 31, 2025 | -390,651.00 |
| Mar 31, 2025 | -390,651.00 |
| Dec 31, 2024 | -1.28 Mn |
| Dec 31, 2024 | -1.28 Mn |
| Sep 30, 2024 | -258,948.00 |
| Sep 30, 2024 | -258,948.00 |
| Jun 30, 2024 | 307,324.00 |
| Jun 30, 2024 | 307,324.00 |
| Mar 31, 2024 | -2.99 Mn |
| Mar 31, 2024 | -2.99 Mn |